MGUS Management

Authored by Vincent Rajkumar, published on 2026-03-24 03:18:01.0

MGUS (Monoclonal Gammopathy of Undetermined Significance) is managed through active surveillance (watchful waiting) to detect potential progression to multiple myeloma or related disorders, rather than immediate treatment. It involves risk-stratified, lifelong monitoring of M-protein levels, free light chains (FLC), and blood counts, typically every 6–12 months.

  1. All patients with MGUS
    • Recheck Labs in 6 months*
      • Stable labs, with no ongoing clinical concerns
        • MGUS Risk Stratification
          • Low risk MGUS, or IgM MGUS <1.5 gm/dl, or FLC abnormality only between 0.125-8.0
            • No further follow up for MGUS needed unless clinical concerns arise
          • All other MGUS
            • Annual labs* and clinical follow up
      • Labs show increase, or other ongoing clinical concerns
        • Work up for plasma cell malignancy or related disorder
          • No evidence of malignancy or related disorder
            • Annual labs* and clinical follow up
          • Evidence of malignancy or related disorder
            • Treat according to diagnosis
tosprivacyHow I Treat In Brief: Managing Monoclonal Gammopathy of Undetermined Significance